Literature DB >> 18039923

Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.

Robert L Holmes1, James H Jorgensen.   

Abstract

We assessed MICs and minimal bactericidal concentrations of vancomycin, daptomycin, and nine other antimicrobials against methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. No vancomycin, daptomycin, or linezolid resistance was observed. Clindamycin, gentamicin, and ciprofloxacin resistance decreased significantly. No tolerance to vancomycin or daptomycin was observed, nor was MIC creep seen.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18039923      PMCID： PMC2224722          DOI： 10.1128/AAC.00945-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 2.  Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.

Authors:  P A Moise; J J Schentag
Journal:  Int J Antimicrob Agents       Date:  2000-11       Impact factor: 5.283

3.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  D P Levine; B S Fromm; B R Reddy
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

4.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

5.  Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.

Authors:  J Ena; A Houston; R P Wenzel; R N Jones
Journal:  J Chemother       Date:  1993-02       Impact factor: 1.714

6.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

Authors:  Pamela A Moise-Broder; George Sakoulas; George M Eliopoulos; Jerome J Schentag; Alan Forrest; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2004-05-21       Impact factor: 9.079

7.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

9.  Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Authors:  Feng-Yee Chang; James E Peacock; Daniel M Musher; Patricia Triplett; Brent B MacDonald; Joseph M Mylotte; Alice O'Donnell; Marilyn M Wagener; Victor L Yu
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections.

Authors:  Cynthia L Maree; Robert S Daum; Susan Boyle-Vavra; Kelli Matayoshi; Loren G Miller
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883
View more
  19 in total

1.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

2.  Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.

Authors:  Maria M Traczewski; Bradley D Katz; Judith N Steenbergen; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

3.  Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Franziska Ludwig; Becky Edwards; Timothy Lawes; Ian M Gould
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

4.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

5.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

Review 6.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid.

Authors:  Stefan Riedel; Kar Mun Neoh; Stephen W Eisinger; Lisa M Dam; Tsigereda Tekle; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2014-04-09       Impact factor: 5.948

8.  Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.

Authors:  Edward O Mason; Linda B Lamberth; Wendy A Hammerman; Kristina G Hulten; James Versalovic; Sheldon L Kaplan
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

9.  Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.

Authors:  Helio S Sader; Paul D Fey; Ajit P Limaye; Nancy Madinger; Douglas N Fish; George Pankey; James Rahal; Michael J Rybak; David R Snydman; Lisa L Steed; Ken Waites; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

10.  Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection.

Authors:  Abhijit Chakraborty; Sandip Roy; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2009-04-22       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.